Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment

Status unconfirmed · Not applicable

Conditions studied: HIV Infections

In brief

The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.

Key facts

Study ID

NCT00006591

Run by

Gathe, Joseph, M.D.

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible for this study if they:
• Are 18 years of age or older.
• Are HIV-positive.
• Have a viral load (level of HIV in the body) of more than 1,000 copies/ml.
• Have had more than 12 weeks of prior anti-HIV drug treatment.
• Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor.
• Are responsive to Agenerase.
• Are able to follow study requirements.

You may not qualify if…

• Patients will not be eligible for this study if they:
• Are intolerant to ritonavir (an anti-HIV drug).
• Have or have had problems with absorption.
• Have liver disease or damage.
• Have pancreatic disease or damage.
• Have taken any protease inhibitor other than nelfinavir.
• Are receiving investigational drugs or devices from another study.
• Are pregnant or breast-feeding.
• Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide.
• Have a bleeding disorder.
• Have previously been treated with Agenerase.
• Are receiving nonnucleosides.

Where it is running

• Gathe, Joseph, M.D. — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.